BMO Capital Markets Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Posted by George Bondi on Oct 12th, 2026

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target lowered by equities research analysts at BMO Capital Markets from $164.00 to $150.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “market perform” rating on the stock. BMO Capital Markets’ target price would suggest a potential upside of 6.24% from the stock’s current price.

NBIX has been the subject of several other reports. Cantor Fitzgerald raised their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Truist Financial boosted their price target on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Mizuho raised shares of Neurocrine Biosciences to a “hold” rating in a research note on Wednesday, September 16th. TD Cowen raised their price objective on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Wall Street Zen lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Sunday, August 9th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.14.

Check Out Our Latest Report on Neurocrine Biosciences

Neurocrine Biosciences Stock Down 0.9%

Shares of NBIX traded down $1.25 during mid-day trading on Monday, hitting $141.19. 268,290 shares of the company’s stock traded hands, compared to its average volume of 1,214,997. The firm has a market capitalization of $14.35 billion, a P/E ratio of 20.70, a PEG ratio of 0.66 and a beta of 0.40. The business’s 50-day moving average price is $151.74 and its 200-day moving average price is $153.37. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $2.85 EPS for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. The company had revenue of $959.00 million during the quarter, compared to analyst estimates of $891.16 million. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The firm’s revenue was up 39.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.65 earnings per share. Sell-side analysts anticipate that Neurocrine Biosciences will post 7.26 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In related news, Director Leslie V. Norwalk sold 1,250 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total value of $227,512.50. Following the completion of the transaction, the director directly owned 1,588 shares in the company, valued at $289,031.88. This trade represents a 44.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Boyer sold 826 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the transaction, the insider owned 8,722 shares of the company’s stock, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 4,387 shares of company stock valued at $720,855 in the last three months. 4.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Basecamp Wealth Advisors LLC grew its stake in shares of Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after buying an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in Neurocrine Biosciences during the first quarter valued at $33,000. Ascentis Independent Advisors bought a new stake in Neurocrine Biosciences in the first quarter worth $40,000. SJS Investment Consulting Inc. boosted its holdings in Neurocrine Biosciences by 67.2% in the first quarter. SJS Investment Consulting Inc. now owns 341 shares of the company’s stock worth $45,000 after acquiring an additional 137 shares in the last quarter. Finally, TrinityBridge Ltd bought a new stake in Neurocrine Biosciences in the second quarter worth $45,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies.

Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease.